A detailed history of Raymond James & Associates transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Raymond James & Associates holds 80,706 shares of SCPH stock, worth $273,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,706
Previous 86,059 6.22%
Holding current value
$273,593
Previous $374,000 1.6%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$4.12 - $5.51 $22,054 - $29,495
-5,353 Reduced 6.22%
80,706 $368,000
Q2 2024

Jul 19, 2024

BUY
$3.51 - $5.21 $3,545 - $5,262
1,010 Added 1.19%
86,059 $374,000
Q1 2024

Apr 22, 2024

SELL
$4.86 - $6.39 $9,720 - $12,780
-2,000 Reduced 2.3%
85,049 $426,000
Q4 2023

Jan 16, 2024

BUY
$4.7 - $6.63 $25,271 - $35,649
5,377 Added 6.58%
87,049 $545,000
Q3 2023

Oct 24, 2023

BUY
$7.0 - $9.82 $30,940 - $43,404
4,420 Added 5.72%
81,672 $581,000
Q2 2023

Jul 25, 2023

BUY
$8.94 - $11.74 $66,164 - $86,887
7,401 Added 10.6%
77,252 $787,000
Q1 2023

Apr 14, 2023

BUY
$5.59 - $9.47 $101,139 - $171,340
18,093 Added 34.96%
69,851 $633,000
Q4 2022

Feb 08, 2023

BUY
$4.02 - $7.53 $208,067 - $389,737
51,758 New
51,758 $371,000

Others Institutions Holding SCPH

About scPharmaceuticals Inc.


  • Ticker SCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,402,100
  • Market Cap $92.9M
  • Description
  • scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...
More about SCPH
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.